ArticleThe Prostate1999
Inhibitory effect of zinc on human prostatic carcinoma cell growth.
Article in The Prostate, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 255 citations in OpenAlex.
- Article
- Multivariate Statistical Evaluation of 20 Metals/Metalloid Levels in the Serum of Patients with Prostate Gland Diseases.Indian journal of clinical biochemistry : IJCB · 2025Article
- Metal-based molecules in the treatment of cancer: From bench to bedside.Oncology research · 2025Review
- Emerging Perspectives in Zinc Transporter Research in Prostate Cancer: An Updated Review.Nutrients · 2024Review
- The role of inflammatory processes and zinc levels in prostatic enlargement among Iraqi samples.Journal of medicine and life · 2023Article
- Zinc: From Biological Functions to Therapeutic Potential.International journal of molecular sciences · 2023Review
- Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting.International journal of molecular sciences · 2023Review
- Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer.International journal of molecular sciences · 2023Review
- Zinc in Prostate Health and Disease: A Mini Review.Biomedicines · 2022Review
- Stage-specific differential expression of zinc transporter SLC30A and SLC39A family proteins during prostate tumorigenesis.Molecular carcinogenesis · 2022Article
- Article
- Dietary Phytochemicals in Zinc Homeostasis: A Strategy for Prostate Cancer Management.Nutrients · 2021Review
- SLC39A8/Zinc Suppresses the Progression of Clear Cell Renal Cell Carcinoma.Frontiers in oncology · 2021Article
- The role of nutritional interventions in prostate cancer: A review.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2021Review
- Exploring a new dinuclear Fe(iii) complex for the fixation of atmospheric CORSC advances · 2020Article
- Zinc: The Wonder Drug for the Treatment of Carcinomas.Acta scientific cancer biology · 2020Article
- Growth Modulatory Role of Zinc in Prostate Cancer and Application to Cancer Therapeutics.International journal of molecular sciences · 2020Review
- Advances of Zinc Signaling Studies in Prostate Cancer.International journal of molecular sciences · 2020Review
- Zinc Inhibits Expression of Androgen Receptor to Suppress Growth of Prostate Cancer Cells.International journal of molecular sciences · 2018Article
- Epigallocatechin gallate-zinc oxide co-crystalline nanoparticles as an anticancer drug that is non-toxic to normal cells.RSC advances · 2018Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundNormal human prostate accumulates the highest levels of zinc of any soft tissue in the body. In contrast, the zinc level in prostate cancer is markedly decreased from the level detected in nonprostate tissues. Despite these relationships, the possible role of zinc in the growth of normal and malignant prostate has not been determined.
methodsGrowth inhibition and various regulatory responses were investigated in two human prostate carcinoma cell lines (LNCaP and PC-3), treated with or without zinc.
resultsIncubation of the prostate carcinoma cell lines with physiological levels of zinc resulted in the marked inhibition of cell growth. A lower 50% inhibition of cell growth (IC50) value for zinc (about 100 ng/ml) was detected in LNCaP cells, which are androgen-responsive, whereas androgen-independent PC-3 cells exhibited a higher IC50 for zinc (about 700 ng/ml). Incubation with 1 microg/ml zinc resulted in maximum inhibition of growth in both cell lines. These inhibitory effects of zinc correlated well with the accumulation of zinc in the cells. Simultaneously, cell flow cytometric analyses revealed a dramatic increase of the cell population in G2/M phase, in both LNCaP (2.3-fold vs. control) and PC-3 (1.9-fold vs. control), and a decreased proportion of cells in S phase (LNCaP, -51.4%; PC-3, -23%), indicating a G2/M phase arrest. The cell growth inhibition and G2/M arrest in these cells were accompanied by an increase in apoptosis, as demonstrated by the characteristic cell morphology and further confirmed by cellular DNA fragmentation. The specificity of zinc-induced apoptosis was identified by ethylenediamine-tetraacetic acid (EDTA)-chelation, which abolished the zinc effect on cellular DNA fragmentation. The zinc-induced G2/M phase arrest and apoptosis were accompanied by increased mRNA levels of p21(Waf1/Cip1/Sdi1) in both LNCaP (p53+/+) and PC-3 (p53-/-) cells.
conclusionsThese results suggest that zinc inhibits human prostatic carcinoma cell growth, possibly due to induction of cell cycle arrest and apoptosis. There now exists strong evidence that the loss of a unique capability to retain high levels of zinc is an important factor in the development and progression of malignant prostate cells.
Indexed as
Identifiers
10398282PMC4465333W1967714958What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.